Gasporox Q3 2024: Growth but below expectations - Redeye

Redeye notes that Gasporox's report came in below Redeye Estimates (RRe) across the board while producing its highest net sales in Q3 yet. Despite being 18% below sales estimates, EBITDA remained just about positive. Although seasonality has decreased, results remain volatile, and extrapolation should be avoided both positively and negatively. Redeye expects to review its estimate, with a downward revision likely.

Länk till analysen i sin helhet: https://www.redeye.se/research/1045631/gasporox-q3-2024-growth-but-below-expectations?utm_source=finwire&utm_medium=RSS